Verge Genomics

Executive Summary

Verge Genomics is a private biotechnology company headquartered in San Francisco, founded in 2015, that leverages an all-in-human, AI-powered drug discovery platform. Unlike traditional approaches that rely heavily on animal models, Verge uses human multi-omics data combined with machine learning to identify novel drug targets and develop therapeutics, with an initial focus on neuroscience. The company's mission is to accelerate the development of better drugs by starting with human biology, thereby increasing the probability of clinical success. Despite being private and not disclosing its pipeline publicly, Verge has positioned itself as a pioneer in AI-driven drug discovery and has raised significant private funding from top-tier investors. The company's platform-driven approach has the potential to address high unmet needs in neurological diseases, where few effective treatments exist.

Upcoming Catalysts (preview)

• Q4 2026Series C or later funding round announcement70% success
• Q2 2027Partnership with a major pharmaceutical company for neuroscience targets50% success
• Q3 2027Initiation of a first-in-human clinical trial for a lead program40% success